P4‐382: Once Upon a Time: Discussing Stories in a Foreign Language as a Therapeutic and Cognitive Intervention for Seniors with MCI and Alzheimer's

Abstract

with no evidence of accumulation over 14 days. At the 560 mg dose, CSF levels of CT1812 correspond to estimated brain concentrations equivalent to 95% receptor occupancy. Conclusions: In healthy volunteers, CT1812 was well tolerated with single doses up to 1120 mg and with multiple doses up to 840 mg in healthy young volunteers and 560 mg in healthy elderly volunteers. Multiple dose exposure of CT1812 corresponded to more than 20x the expected minimum therapeutic dose while CSF analysis indicated that brain concentrations exceeded the minimum target expected to improve memory (>80% receptor occupancy). CT1812 is designed to directly test the oligomer hypothesis of AD treatment. Further development will test the ability of CT1812 to improve cognitive ability in AD patients.